{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T10:50:07Z","timestamp":1758279007509,"version":"3.41.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of the Report<\/jats:title>\n            <jats:p>Endometrial cancer is the most common gynecological cancer. Prostate-specific membrane antigen (PSMA) is expressed in prostate cancer cells but can be found in other cancers, such as endometrial cancer, during angiogenesis.<\/jats:p>\n            <jats:p>The aim of this prospective pilot study was to evaluate the feasibility of using <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT in endometrial cancer patients before surgical treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Seven women with a mean age of 58 \u00b1 7.9 years were included in the study. All patients underwent standard imaging studies involving transvaginal ultrasound, ceCT scans of the chest and abdomen, and MRI as qualified for surgery. Additionally, PET\/CT was performed on a Siemens Biograph scanner 60 minutes after the injection of 2 MBq\/kg <jats:sup>68<\/jats:sup>Ga-PSMA-11.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Six of 7 patients had positive <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT images, and histopathology confirmed endometrial cancer. One patient also exhibited uptake in the left ovary, and final histopathology revealed a hemorrhagic cyst. Lymph node involvement was further confirmed after ceCT fusion with <jats:sup>68<\/jats:sup>Ga-PSMA-11. The consensus of histopathological staging of endometrial cancer and ceCT was 4\/7, that of MR was 6\/7, and that of <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT was 5\/7. All methods were consistent in terms of staging in 3\/7 patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The initial experience showed the possibility of using <jats:sup>68<\/jats:sup>Ga-PSMA-11 in endometrial cancer patients. However, prospective large studies are needed to explore the real diagnostic role of radiolabelled PSMA in this field.<\/jats:p>\n            <jats:p>This study was approved by the Ethical Committee of the Medical University of Warsaw (KB\/2\/A\/2018).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005446","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T19:00:15Z","timestamp":1730487615000},"page":"e650-e655","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["68Ga-Prostate-Specific Membrane Antigen PET\/CT in Endometrial Cancer: A Preliminary Report"],"prefix":"10.1097","volume":"49","author":[{"given":"Jolanta","family":"Kunikowska","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kacper","family":"Pe\u0142ka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Bizo\u0144","sequence":"additional","affiliation":[{"name":"LUX MED Oncology Hospital, Warsaw, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Olszewski","sequence":"additional","affiliation":[{"name":"LUX MED Oncology Hospital, Warsaw, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/ijc.31961","article-title":"Risk factors for endometrial cancer: an umbrella review of the literature","volume":"145","year":"2019","journal-title":"Int J Cancer"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ijgo.14923","article-title":"FIGO staging of endometrial cancer: 2023","volume":"162","year":"2023","journal-title":"Int J Gynecol Obstet"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.3390\/ijms22179274","article-title":"Molecular basis of endometriosis and endometrial cancer: current knowledge and future perspectives","volume":"22","year":"2021","journal-title":"Int J Mol Sci"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/PGP.0000000000000585","article-title":"Molecular classification and emerging targeted therapy in endometrial cancer","volume":"39","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"bib6-20250621","first-page":"12","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","year":"2021","journal-title":"Int J Cancer"},{"journal-title":"J Magn Reson Imaging","article-title":"Preoperative imaging evaluation of endometrial cancer in FIGO 2023","year":"2023","key":"bib7-20250621"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/IGC.0000000000001076","article-title":"Clinical utility of preoperative computed tomography in patients with endometrial cancer","volume":"27","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"bib9-20250621","first-page":"692","article-title":"Computed tomography in endometrial cancer","volume":"95","year":"2000","journal-title":"Obstet Gynecol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ijgo.14609","article-title":"Transvaginal ultrasound versus magnetic resonance imaging for diagnosing adenomyosis: a systematic review and head-to-head meta-analysis","volume":"161","year":"2023","journal-title":"Int J Gynaecol Obstet"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/13645706.2019.1624576","article-title":"PET-CT scan in the preoperative workup of early stage intermediate- and high-risk endometrial cancer","volume":"29","year":"2020","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"181","DOI":"10.6004\/jnccn.2023.0006","article-title":"Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology","volume":"21","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3390\/jcm10081746","article-title":"FDG-PET\/CT and para-aortic staging in endometrial cancer. A French multicentric study","volume":"10","year":"2021","journal-title":"J Clin Med"},{"key":"bib14-20250621","first-page":"3629","article-title":"Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium","volume":"57","year":"1997","journal-title":"Cancer Res"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/1055-9965.EPI-07-0511","article-title":"Prostate-specific membrane antigen expression is a potential prognostic marker in endometrial adenocarcinoma","volume":"17","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/PAI.0000000000000297","article-title":"Prostate-specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies: implications for PSMA-targeted therapy","volume":"25","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/RLU.0000000000002806","article-title":"68Ga\u2013prostate-specific membrane antigen-11 PET\/CT: a new imaging option for recurrent glioblastoma multiforme?","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.semnuclmed.2023.07.003","article-title":"Prognostic value of PSMA PET\/CT in prostate cancer","volume":"54","year":"2024","journal-title":"Semin Nucl Med"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1097\/RLU.0000000000004903","article-title":"68Ga-PSMA-11 PET\/CT imaging in brain gliomas and its correlation with clinicopathological prognostic parameters","volume":"48","year":"2023","journal-title":"Clin Nucl Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3390\/jpm12040551","article-title":"Prostate-specific membrane antigen (PSMA) expression in tumor-associated neovasculature is an independent prognostic marker in patients with ovarian cancer","volume":"12","year":"2022","journal-title":"J Pers Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"e1329","DOI":"10.1002\/ctm2.1329","article-title":"Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates","volume":"13","year":"2023","journal-title":"Clin Transl Med"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"bib24-20250621","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00259-020-04715-z","article-title":"Tumor uptake in glioblastoma multiforme after IV injection of [177Lu]Lu-PSMA-617","volume":"47","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00259-020-05017-0","article-title":"[68Ga]Ga-prostate-specific membrane antigen PET\/CT: a novel method for imaging patients with hepatocellular carcinoma","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients","volume":"44","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:06:37Z","timestamp":1750532797000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005446","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"type":"electronic","value":"1536-0229"},{"type":"print","value":"0363-9762"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}